| Safety and regulation
The FDA Pharmacy Compounding Advisory Committee met July 23 and 24, 2026. It voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A bulks list, and voted against emideltide (DSIP). The closest recommended votes were 7 to 5 for MOTS-c and 8 to 6 for BPC-157, KPV and TB-500.
Worth knowing: The votes are advice, not a rule, and not an approval. Reports say FDA staff recommended against all seven.
Related: Peptide policy tracker | What a 503A pharmacy is
Source: U.S. Food and Drug Administration meeting page. Page content current as of August 6, 2026 Regulator. McDermott Will & Schulte law-firm client alert, July 27, 2026. Secondary source Trade press, secondary source. Healio, July 24, 2026 (page modified September 15, 2026). Trade press report Trade press, secondary source.